In the context of pharmacotherapy, pharmacological (VS) and psychologically enhance mood and attention.
Introduction an event-related fMRI probe called the monetary incentive delay (MID) task, which was designed to elicit neural The capacity of functional magnetic resonance imaging and affective responses to quantifiable incentives (Knut-(fMRI) to resolve the activity in small subcortical regions son et al., 2000). During the MID task, subjects are cued in real time has advanced the study of incentive proto anticipate potential monetary gains and losses and cessing. Incentive processing refers to an organism's then respond to a rapidly presented target to either response to both appetitive and aversive incentives over acquire the gains or avoid the losses. Previous research time, including both anticipatory and consummatory using this task suggests that while anticipation of gains phases (Craig, 1918) . By combining event-related fMRI elicits VS activity, gain outcomes elicit MPFC activity designs with different incentives ranging from juice to (Knutson et al., 2001b (Knutson et al., , 2003 . Additionally, gain anticipamoney, several laboratories have now been able to replition elicits increased positive aroused affect, which is cate functional dissociations in neural substrates assocorrelated with VS activity (Bjork et AMPH can alter mood and attention (Wachtel and de Wit, 1999) in a manner that could be characterized as increased positive and aroused mood, or "positive cant main effects of valence and magnitude on "excited" arousal" (Watson et al., 1999) . Thus, AMPH might inreactions to cues, these were qualified by the predicted crease positive arousal in response to incentive cues.
higher cues. Thus, AMPH appeared to exert an "equalizing" Because the MID task was designed to probe affect and influence on incentive cue-elicited positive arousal, such neural activity while controlling for behavioral perforthat treated subjects felt similar levels of excitement mance, we predicted no significant effects of treatment, during anticipation of both positive and negative largeorder, or condition on performance. As predicted, a 2 magnitude incentives (see Figure 1 ). (drug) ϫ 2 (dose order) ϫ 2 (valence) ϫ 4 (magnitude) repeated measures ANOVA on hit rate revealed no significant main effects or interactions. These findings sugBrain Activity Statistical Maps gested that subjects performed similarly during scans 1 and 2 and that performance was not significantly modUsing a voxel-based analysis, we examined the replicability of prior findings of NAcc and medial caudate ulated by drug treatment or dose order. Across all trial types, average performance approximated the targeted activation during anticipation of gain versus nongain as well as MPFC, posterior cingulate, and parietal activa-66% hit rate (mean ϭ 66%, SD ϭ 10%). A 2 (drug) ϫ 2 (dose order) repeated measures ANOVA on total monetion in response to gain versus nongain outcomes under PLAC treatment. Additionally, we examined whether tary earnings also revealed no significant main effects or interactions of drug treatment or dose order. Thus, AMPH treatment would alter either qualitative (i.e., localization) or quantitative (i.e., intensity) aspects of these because subjects consistently performed at maximum capacity, performance did not differ across scan sessions, activation patterns. Table 1 ). ANOVAs revealed significant main effects of valence and magnitude on affective reactions to cues (i.e., "happy,"
Loss versus Nonloss Anticipation. Under PLAC treatment, loss versus nonloss anticipation deactivated the "unhappy," "fearful"), qualified by significant interactions of magnitude by valence (all p Ͻ .001). As in prior left MPFC and bilateral posterior cingulate. Under AMPH treatment, loss versus nonloss anticipation activated research, subjects had more positive reactions ("happy" and "excited") to ϩ$1.00 and ϩ$5.00 cues relative the left NAcc, left medial caudate, and left anterior insula, but deactivated the bilateral MPFC and left posteto ϩ$0.00 cues as well as more negative reactions ("unhappy" and "fearful") to Ϫ$1.00 and Ϫ$5.00 cues relative rior cingulate. Thus, regions of deactivation were similar for PLAC and AMPH treatment, with some additional to Ϫ$0.00 cues. However, while there were also signifi- prior findings of an interaction of valence and magnitude on right NAcc activation replicated but were additionally sponse to gain outcomes. Thus, we directly compared peak activation (i.e., signal at lag ϭ 6 s) in VOIs centered modulated by drug treatment status, such that AMPH treatment appeared to "equalize" activation during anin foci previously activated by gain versus nongain antic- Figure 3) .
were not merely due to temporal correlation in the signal.
Volume of Interest Analysis: Time Course
Thus, while these results suggest that AMPH treatment To determine whether AMPH treatment might have modmay have blunted peak NAcc activity during anticipation ulated the shape of the hemodynamic response function (i.e., time point 4; 6 s), they also are also not inconsistent in the VS, we extracted and compared activation time with the hypothesis that AMPH treatment may have procourses from the right NAcc for trial types that showed longed NAcc activity at later time points (i.e., time point maximal differences (i.e., Ϯ$5.00 and Ϯ$0.00 "hit" trials). 7; 12 s) (see Figure 4 ). Right NAcc VOI data for ϩ$5.00 gain trials were subSimilar analyses of potential loss trials did not reveal jected to a 2 (AMPH versus PLAC treatment) ϫ 9 (epoch) significant differences between PLAC and AMPH ANOVA, which revealed a significant main effect of epduring Ϫ$5.00 trials. For gain outcomes, we predicted a significant interaction of drug, valence, magnitude, and outcome (but not dose order) on MPFC activation. Paired t tests were used to decompose interactions and fMRI Analysis test for differences at predicted time points (p Ͻ 0.05, two-tailed). Analyses focused both on changes in blood oxygen level-dependent To examine the NAcc hemodynamic response function under AMPH contrast (or "activation") that occurred during anticipatory delay versus PLAC treatment, we compared activation at each of the nine periods as well as on activations that occurred during outcome acquisitions during and following the cue presentation during each periods. All analyses were conducted using Analysis of Functional of the ϩ$5.00, Ϫ$5.00, ϩ$0.00, and Ϫ$0.00 trials. These trial types Neural Images (AFNI) software (Cox, 1996). For preprocessing, voxel were selected because anticipatory activation changes most roactivation time series were interpolated to correct for nonsimultanebustly under high incentive conditions (Knutson et al., 2001a ). ous slice acquisition within each volume (using sinc interpolation and the most inferior slice as a reference), concatenated across both task sessions, corrected for three-dimensional motion (using Performance the third volume of the first session as a reference), subjected to Percentage of hits and hit reaction times on each trial type were slight spatial blurring to increase the signal to noise ratio (4 mm averaged for each individual and subjected to repeated measures FWHM), and bandpass filtered to remove the influence of nonlinear within-subjects 2 (drug) ϫ 2 (dose order) ϫ 2 (valence) ϫ 4 (magnitrends unrelated to the task frequency (i.e., Ͻ6 and Ͼ90 s). Visual tude) ANOVAs. We predicted no significant effects of any variable inspection of motion correction estimates confirmed that no particion performance, since the practice task was designed to enable pant's head moved more than 2 mm in any dimension from one investigators to control for performance such that subjects pervolume acquisition to the next. Two other volunteers had violated formed at ceiling across conditions during scanning. In the event this criterion on one of the two scanning sessions and so were of a significant interaction, paired t tests were used to compare excluded from further analyses, leaving a total of 8 subjects. Paired differences among trial types (p Ͻ 0.05, two-tailed, uncorrected). comparisons of movement estimate standard deviations in the x, y, and z planes assured that remaining subjects did not significantly differ under AMPH versus PLAC treatment. Mean-corrected ratings for each cue type were then subjected to versus nonloss outcome; (4) outcomes versus the rest of the trial; repeated measures within-subjects 2 (drug) ϫ 2 (dose order) ϫ 2 (5) "hit" versus "miss" outcomes on potential gain trials; and (6) (valence) ϫ 4 (magnitude) ANOVAs. In accord with prior findings, "hit" versus "miss" outcomes on potential loss trials. Regressors of we predicted a significant drug ϫ valence ϫ magnitude (but not interest were convolved with a ␥-variate function that modeled a dose order) interaction on adjectives most indicative of positive prototypical hemodynamic response prior to inclusion in the regresarousal (e.g., "excitement"), but not on other adjectives (Bjork et sion model (Cohen, 1997) . Maps of t statistics for these regressors of al., 2004). In the event of a significant interaction, paired t tests interest were transformed into Z scores, coregistered with structural were used to compare differences within trial types across drug maps, spatially normalized by warping to Talairach space, slightly conditions (p Ͻ 0.05, two-tailed, uncorrected). spatially smoothed (FWHM ϭ 2 mm) to minimize the effects of anatomical variability, resampled at 2 mm cubic, and combined into a group map using a meta-analytic formula (average Z*sqrt(n)). Analy
